Health Sciences Conference Papers

Permanent URI for this collection


Recent Additions

Now showing 1 - 5 of 22
  • Item
    Yttrium-90 based bremsstrahlung Imaging with a solid state detector gamma camera: A first imaging experience with GE-NM CT 850
    (Society of Nuclear Medicine and Molecular Imaging, 2023-08-28) Vyas, Madhusudan; Chandershekar, R.; Mafi, N.; Fagan, J.; Henderson, A.; Unitec, Te Pūkenga; Te Pūkenga; Mer; Journal of Nuclear Medicine
    INTRODUCTION Yttrium-90 (Y90) is an efficient therapeutic radioisotope for tumour treatment due to its high-energy beta rays. However, due to the vast energy spectra of Y-90, its always been challenging for Y-90 Bremsstrahlung imaging with traditional Phtomultipliar tube-based Anger gamma cameras. In the last few years, the solid-state gamma camera with a Caediumium Zinc Telluride (CZT) crystal has changed the imaging experience due to its direct conversions of signals and high signal-to-noise ratio, which produces high spatial and contrast resolution in the images compared to the traditional Anger PMT-based gamma camera. This presentation explained our site’s experience of post-Y90 Bremstrulung imaging, probably the first globally with the general electronics (GE)© NM CT870 model.
  • Item
    FAP still more question to be answered: A review-based analysis
    (Society of Nuclear Medicine and Molecular Imaging, 2023-08-28) Vyas, Madhusudan; Glassunburry, A.; Unitec, Te Pūkenga; Mercy Radiology (Auckland, N.Z.); Journal of Nuclear Medicine
    Over ninety percent of epithelial malignancies have elevated levels of fibroblast activation protein (FAP), a type II transmembrane serine protease that is closely associated with tumour invasion, metastasis, and prognosis. Using FAP as a target, different FAP inhibitors (FAPIs) have been developed; the majority of these FAPIs have nanomolar levels of FAP affinity and high selectivity, and they are used for positron emission tomography (PET) imaging of diverse cancers. FAPIs are projected to be the new molecule of the century with greater imaging effects than 18F-FDG in a number of diseases, such as gastrointestinal tumours, liver tumours, breast tumours, and nasopharyngeal carcinoma, based on current research. FAPIs are a complementing molecular imaging method to 18F-FDG. Current paper present the review of currebntly published litreature in terms of FAPI and its clinical role in oncology.
  • Item
    An overview of radiochemical identity and radiochemical purity of 18F-FDG and factor affecting the RCP
    (Society of Nuclear Medicine and Molecular Imaging, 2023-08-28) Vyas, Madhusudan; Sharma, Sandeep; Unitec, Te Pūkenga; Futuristic Diagnostic Imaging (Bangalore, India); Journal of Nuclear Medicine
    INTRODUCTION The radiopharmaceutical known as fluorodeoxyglucose (18F-FDG) is the one that is utilised most frequently in PET-CT imaging. In the first place, it is applied to the diagnosis and evaluation of various stages of cancer. Because it has such a wide variety of applications, the use of 18F-FDG has expanded. In order to produce 18F-FDG, a multi-step procedure must be followed. These steps include the following: production of 18F-fluoride in a cyclotron by bombarding 16O-water with a proton beam; trapping of 18F-fluoride in an ion exchange column (QMA) in the synthesis module; elution of 18F-fluoride from the QMA column by TBA or Kryprofix solution; azeotropic drying; mannose triflate Following the completion of the purification process, the final product is collected in a sterile vial after going through a sterile filter with a pore size of 0.22 microns and being further filtered. Both the radiochemical identity (RI) and the radiochemical purity (RCP) are essential quality control characteristics; hence, it is essential that they be evaluated using techniques that have been authorised and validated, and the findings of the test need to satisfy the requirements for batch release. A low RCP can result in a low target-to-non-target ratio, an increase in blood pool or background activity, poor picture quality, a compromised diagnosis, and an increased radiation dosage to the patient as a result of a change in the biological half-life or the necessity of a repeat examination.
  • Item
    Yacon prebiotic functional drinks, the sensory and antioxidant profiles: Dietotherapy applications of yacon concentrate
    (2022-12-02) Yan, Mary; Chessum, K.; Nand, Saleshni; Terzaghi, B.; Kam, R.; Unitec, Te Pūkenga; Te Pūkenga
    Yacon Health-related properties Aim of the study Development of yacon functional drinks Sensory evaluation Antioxidant capacity Shelf-life Conclusions Further work Acknowledgements: The team • Dr Rothman Kam, Keegan Chessum, Saleshni Nand, Ben Terzaghi This research was co-funded by Te Pūkenga Unitec and Yacon New Zealand Ltd.
  • Item
    A first NZ study looked at the role of Lutetium-177-PSMA I & T in the progression of mCRPC
    (2022-07-23) Vyas, Madhusudan; Unitec Institute of Technology
    OBJECTIVES To assess the efficacy of Lutetium-177-PSMA-I&T therapy to palliate end stage mCRPC To review tolerability and impact on QOL of Lutetium-177- PSMA-I&T therapy